Dósa E, et al. - Experts sought to establish the maximum tolerated dose (MTD) and pharmacokinetics of both intravenous (IV) and intra-arterial (IA) N-acetylcysteine (NAC) in adults with chronic kidney disease to be used in further trials on oto- and nephroprotection in pediatric patients receiving platinum therapy. At a dose of 450 mg/kg, NAC could be safely given both IV and IA in adults with kidney impairment. To confirm oto- and nephroprotective properties in the setting of cisplatin treatment, further studies were required.